Dysregulated gene expression networks in human acute myelogenous leukemia stem cells
Majetl, R., Becker, M. W., Tian, Q., Lee, T.-L. M., Yan, X., Liu, R., … Weissman, I. L. (2009). Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(9), 3396–3401.

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., … Weissman, I. L. (2009). CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis. CELL, 138(2), 271–85.

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., … Weissman, I. L. (2009). CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells. CELL, 138(2), 286–99.

Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)
Medeiros, B. C., Kohrt, H. E., Arber, D. A., Bangs, C. D., Cherry, A. M., Majeti, R., … Alizadeh, A. A. (2010). Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). LEUKEMIA RESEARCH, 34(5), 594–97.

Macrophages as mediators of tumor immunosurveillance
Jaiswal, S., Chao, M. P., Majeti, R., & Weissman, I. L. (2010). Macrophages as mediators of tumor immunosurveillance. TRENDS IN IMMUNOLOGY, 31(6), 212–19.

Metastatic Cancer Stem Cells: An Opportunity for Improving Cancer Treatment?
Diehn, M., & Majeti, R. (2010). Metastatic Cancer Stem Cells: An Opportunity for Improving Cancer Treatment? CELL STEM CELL, 6(6), 502–3.

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., … Majeti, R. (2010). Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma. CELL, 142(5), 699–713.

Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., … Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877–81.

Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells
Majeti, R. (2011). Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. ONCOGENE, 30(9), 1009–1019.

Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., … Majeti, R. (2011). Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia. CANCER RESEARCH, 71(4), 1374–84.

Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia
Gentles, A. J., Plevritis, S. K., Majeti, R., & Alizadeh, A. A. (2010). Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 304(24), 2706–15.

Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47
Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., … Weissman, I. L. (2010). Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47. SCIENCE TRANSLATIONAL MEDICINE, 2(63).

Human Acute Myelogenous Leukemia Stem Cells Revisited: There's More Than Meets the Eye
Majeti, R., & Weissman, I. L. (2011). Human Acute Myelogenous Leukemia Stem Cells Revisited: There's More Than Meets the Eye. CANCER CELL, 19(1), 9–10.

Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments
Gibbs, K. D., Gilbert, P. M., Sachs, K., Zhao, F., Blau, H. M., Weissman, I. L., … Majeti, R. (2011). Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments. BLOOD, 117(16), 4226–33.

Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker
Jan, M., Chao, M. P., Cha, A. C., Alizadeh, A. A., Gentles, A. J., Weissman, I. L., & Majeti, R. (2011). Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 108(12), 5009–14.

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy
Chao, M. P., Tang, C., Pachynski, R. K., Chin, R., Majeti, R., & Weissman, I. L. (2011). Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. BLOOD, 118(18), 4890–4901.

Surprise! HSC Are Aberrant in Chronic Lymphocytic Leukemia
Alizadeh, A. A., & Majeti, R. (2011). Surprise! HSC Are Aberrant in Chronic Lymphocytic Leukemia. CANCER CELL, 20(2), 135–36.

Treatment advances have not improved the early death rate in acute promyelocytic leukemia
McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., Alizadeh, A. A., & Medeiros, B. C. (2012). Treatment advances have not improved the early death rate in acute promyelocytic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 133–36.

Programmed cell removal: a new obstacle in the road to developing cancer.
Chao, M. P., Majeti, R., & Weissman, I. L. (2012). Programmed cell removal: a new obstacle in the road to developing cancer. Nature Reviews. Cancer, 12(1), 58–67.

The CD47-SIRP alpha pathway in cancer immune evasion and potential therapeutic implications
Chao, M. P., Weissman, I. L., & Majeti, R. (2012). The CD47-SIRP alpha pathway in cancer immune evasion and potential therapeutic implications. CURRENT OPINION IN IMMUNOLOGY, 24(2), 225–32.

Clonal evolution of acute leukemia genomes
Jan, M., & Majeti, R. (2013). Clonal evolution of acute leukemia genomes. ONCOGENE, 32(2), 135–40.

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., … Weissman, I. L. (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(17), 6662–67.

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma
Edris, B., Weiskopf, K., Volkmer, A. K., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., … van de Rijn, M. (2012). Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(17), 6656–61.

Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia
Jan, M., Snyder, T. M., Corces-Zimmerman, M. R., Vyas, P., Weissman, I. L., Quake, S. R., & Majeti, R. (2012). Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia. SCIENCE TRANSLATIONAL MEDICINE, 4(149).

The cancer stem cell model: B cell acute lymphoblastic leukaemia breaks the mould.
McClellan, J. S., & Majeti, R. (2013). The cancer stem cell model: B cell acute lymphoblastic leukaemia breaks the mould. EMBO Molecular Medicine, 5(1), 7–9.

Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen
Ochsenreither, S., Majeti, R., Schmitt, T., Stirewalt, D., Keilholz, U., Loeb, K. R., … Greenberg, P. D. (2012). Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. BLOOD, 119(23), 5492–5501.

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
Craddock, C., Quek, L., Goardon, N., Freeman, S., Siddique, S., Raghavan, M., … Vyas, P. (2013). Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. LEUKEMIA, 27(5), 1028–36.

Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.
Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., Kohrt, H. E., & Medeiros, B. C. (2009). Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. BLOOD, 114(22), 420–21.

Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib
Huang, M., Thomas, D., Li, M. X., Feng, W., Chan, S. M., Majeti, R., & Mitchell, B. S. (2013). Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib. LEUKEMIA, 27(10), 1970–80.

Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib, J. R., … Alizadeh, A. A. (2009). Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). BLOOD, 114(22), 646–47.

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.
Corces-Zimmerman, M. R., Hong, W.-J., Weissman, I. L., Medeiros, B. C., & Majeti, R. (2014). Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proceedings of the National Academy of Sciences of the United States of America, 111(7), 2548–53.

Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
Chan, S. M., & Majeti, R. (2013). Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. INTERNATIONAL JOURNAL OF HEMATOLOGY, 98(6), 648–57.

Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.
Lee, J. Y., Hong, W.-J., Majeti, R., & Stearns, T. (2014). Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms. PloS One, 9(3).

Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.
Green, M. R., Vicente-Dueñas, C., Romero-Camarero, I., Long Liu, C., Dai, B., González-Herrero, I., … Sánchez-García, I. (2014). Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nature Communications, 5, 3904-?

Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma
Green, M. R., Vicente-Duenas, C., Romero-Camarero, I., Liu, C. L., Dai, B., Gonzalez-Herrero, I., … Sanchez-Garcia, I. (2014). Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. NATURE COMMUNICATIONS, 5.

Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.
Lee, J. Y., Hong, W.-J., Majeti, R., & Stearns, T. (2014). Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms. PloS One, 9(3).

Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells.
Nguyen, L. X. T., Chan, S. M., Ngo, T. D., Raval, A., Kim, K. K., Majeti, R., & Mitchell, B. S. (2014). Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells. Blood, 124(4), 579–89.

Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition.
Sinha, S., Thomas, D., Yu, L., Gentles, A. J., Jung, N., Corces-Zimmerman, M. R., … Majeti, R. (2015). Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. Blood, 125(2), 316–26.

Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation.
Reinisch, A., Etchart, N., Thomas, D., Hofmann, N. A., Fruehwirth, M., Sinha, S., … Strunk, D. (2015). Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood, 125(2), 249–60.

Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia
Majeti, R. (2014). Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 27(3-4), 229–234.

Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab
Chao, M. P., Hong, J., Kunder, C., Lester, L., Schrier, S. L., & Majeti, R. (2015). Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab. AMERICAN JOURNAL OF HEMATOLOGY, 90(1), 78–81.

Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis
Corces-Zimmerman, M. R., & Majeti, R. (2014). Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. LEUKEMIA, 28(12), 2276–82.

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W.-J., … Majeti, R. (2015). Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Medicine, 21(2), 178–84.

Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages
McClellan, J. S., Dove, C., Gentles, A. J., Ryan, C. E., & Majeti, R. (2015). Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 112(13), 4074–79.

Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands
Moraga, I., Wernig, G., Wilmes, S., Gryshkova, V., Richter, C. P., Hong, W.-J., … Garcia, K. C. (2015). Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands. CELL, 160(6), 1196–1208.

Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells
Reinisch, A., Chan, S. M., Thomas, D., & Majeti, R. (2015). Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. SEMINARS IN HEMATOLOGY, 52(3), 150–64.

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells
Piccione, E. C., Juarez, S., Liu, J., Tseng, S., Ryan, C. E., Narayanan, C., … Majeti, R. (2015). A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MABS, 7(5), 946–56.

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.
Piccione, E. C., Juarez, S., Liu, J., Tseng, S., Ryan, C. E., Narayanan, C., … Majeti, R. (2015). A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs, 7(5), 946–56.

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., … Majeti, R. (2015). Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. PloS One, 10(9).

An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis
Jung, N., Dai, B., Gentles, A. J., Majeti, R., & Feinberg, A. P. (2015). An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. NATURE COMMUNICATIONS, 6.

Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo
Zhang, M., Hutter, G., Kahn, S. A., Azad, T. D., Gholamin, S., Xu, C. Y., … Cheshier, S. H. (2016). Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo. PLOS ONE, 11(4).

A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells
Reinisch, A., Thomas, D., Corces, M. R., Zhang, X., Gratzinger, D., Hong, W.-J., … Majeti, R. (2016). A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. NATURE MEDICINE, 22(7), 812–21.

Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation.
Mazumdar, C., Shen, Y., Xavy, S., Zhao, F., Reinisch, A., Li, R., … Majeti, R. (2015). Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. Cell Stem Cell, 17(6), 675–88.

Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity.
Jonas, B. A., Johnson, C., Gratzinger, D., & Majeti, R. (2016). Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity. PloS One, 11(7).

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., … Sage, J. (2016). CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. JOURNAL OF CLINICAL INVESTIGATION, 126(7), 2610–20.

Burning Fat Fuels Leukemic Stem Cell Heterogeneity.
Thomas, D., & Majeti, R. (2016). Burning Fat Fuels Leukemic Stem Cell Heterogeneity. Cell Stem Cell, 19(1), 1–2.

ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
Zhu, L., Li, Q., Wong, S. H. K., Huang, M., Klein, B. J., Shen, J., … Cleary, M. L. (2016). ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia. Cancer Discovery, 6(7), 770–83.

Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells.
Huang, M., Garcia, J. S., Thomas, D., Zhu, L., Nguyen, L. X. T., Chan, S. M., … Mitchell, B. S. (2016). Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells. Oncotarget.

Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution.
Corces, M. R., Buenrostro, J. D., Wu, B., Greenside, P. G., Chan, S. M., Koenig, J. L., … Chang, H. Y. (2016). Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nature Genetics, 48(10), 1193–1203.

Programmed cell removal: a new obstacle in the road to developing cancer
Chao, M. P., Majeti, R., & Weissman, I. L. (2012). Programmed cell removal: a new obstacle in the road to developing cancer. NATURE REVIEWS CANCER, 12(1), 58–67.

CRISPR/Cas9 ß-globin gene targeting in human haematopoietic stem cells.
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., … Porteus, M. H. (2016). CRISPR/Cas9 ß-globin gene targeting in human haematopoietic stem cells. Nature.

The role of mutations in the cohesin complex in acute myeloid leukemia.
Mazumdar, C., & Majeti, R. (2016). The role of mutations in the cohesin complex in acute myeloid leukemia. International Journal of Hematology, -?

SIRP alpha-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells
Piccione, E. C., Juarez, S., Tseng, S., Liu, J., Stafford, M., Narayanan, C., … Majeti, R. (2016). SIRP alpha-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells. CLINICAL CANCER RESEARCH, 22(20), 5109–19.

Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.
Chao, M. P., Gentles, A. J., Chatterjee, S., Lan, F., Reinisch, A., Corces, M. R., … Majeti, R. (2017). Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell, 20(3), 329–44 e7.

Disrupting the CD47-SIRP alpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
Gholamin, S., Mitra, S. S., Feroze, A. H., Liu, J., Kahn, S. A., Zhang, M., … Cheshier, S. H. (2017). Disrupting the CD47-SIRP alpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. SCIENCE TRANSLATIONAL MEDICINE, 9(381).

Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
Matre, P., Velez, J., Jacamo, R., Qi, Y., Su, X., Cai, T., … Konopleva, M. (2016). Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. ONCOTARGET, 7(48), 79708–79721.

The role of mutations in the cohesin complex in acute myeloid leukemia
Mazumdar, C., & Majeti, R. (2017). The role of mutations in the cohesin complex in acute myeloid leukemia. INTERNATIONAL JOURNAL OF HEMATOLOGY, 105(1), 31–36.

Biology and relevance of human acute myeloid leukemia stem cells.
Thomas, D., & Majeti, R. (2017). Biology and relevance of human acute myeloid leukemia stem cells. Blood.

Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.
Sinha, S., Thomas, D., Chan, S., Gao, Y., Brunen, D., Torabi, D., … Dill, D. L. (2017). Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nature Communications, 8, 15580-?

Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.
Sinha, S., Thomas, D., Chan, S., Gao, Y., Brunen, D., Torabi, D., … Dill, D. L. (2017). Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nature Communications, 8, 15580-?

Super-Enhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML Including an RARa Dependency Targetable by SY-1425, a Potent and Selective RARa Agonist.
McKeown, M. R., Corces, M. R., Eaton, M. L., Fiore, C., Lee, E., Lopez, J. T., … Majeti, R. (2017). Super-Enhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML Including an RARa Dependency Targetable by SY-1425, a Potent and Selective RARa Agonist. Cancer Discovery.

Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6.
Bak, R. O., Dever, D. P., Reinisch, A., Cruz Hernandez, D., Majeti, R., & Porteus, M. H. (2017). Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6. ELife, 6.

Engineering complex genotypes in primary haematopoietic cells using Cas9/sgRNA and AAV donor vectors
Bak, R. O., Dever, D. P., Reinisch, A., Cruz, D., Majeti, R., & Porteus, M. H. (2017). Engineering complex genotypes in primary haematopoietic cells using Cas9/sgRNA and AAV donor vectors. HUMAN GENE THERAPY, 28(12), A17.

CD99 IDENTIFIES DISEASE STEM CELLS IN ACUTE MYELOID LEUKEMIA (AML) AND THE MYELODYSPLASTIC SYNDROMES (MDS)
Chung, S., Pang, W., Jan, M., Klimek, V., Weissman, I., Majeti, R., & Park, C. (2013). CD99 IDENTIFIES DISEASE STEM CELLS IN ACUTE MYELOID LEUKEMIA (AML) AND THE MYELODYSPLASTIC SYNDROMES (MDS). EXPERIMENTAL HEMATOLOGY, 41(8), S16.

FACS-Based Enrichment of a Highly Purified HBB-Targeted Hematopoietic Stem and Progenitor Cell Population Using rAAV6 and CRISPR/Cas9
Dever, D. P., Bak, R. O., Camarena, J., Saxena, N., Reinisch, A., Nicolas, C. E., … Porteus, M. H. (2016). FACS-Based Enrichment of a Highly Purified HBB-Targeted Hematopoietic Stem and Progenitor Cell Population Using rAAV6 and CRISPR/Cas9. MOLECULAR THERAPY, 24, S17.

Sticking It to the Niche: CD98 Mediates Critical Adhesive Signals in AML
Reinisch, A., & Majeti, R. (2016). Sticking It to the Niche: CD98 Mediates Critical Adhesive Signals in AML. CANCER CELL, 30(5), 662–64.

SUPER-ENHANCER ANALYSIS DEFINES NOVEL AML AND MDS SUB-TYPES SENSITIVE TO SY-1425, A POTENT AND SELECTIVE RARA AGONIST
Mckeown, M., Lee, E., Fiore, C., Eaton, M., Lopez, J., Corces-Zimmerman, R., … Olson, E. (2016). SUPER-ENHANCER ANALYSIS DEFINES NOVEL AML AND MDS SUB-TYPES SENSITIVE TO SY-1425, A POTENT AND SELECTIVE RARA AGONIST. HAEMATOLOGICA, 101, 325.

Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia
Jan, M., Snyder, T. M., Corces-Zimmerman, M. R., Weissman, I. L., Quake, S. R., & Majeti, R. (2012). Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia. CANCER RESEARCH, 72.

Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia
Sykes, S. M., Kokkaliaris, K. D., Milsom, M. D., Levine, R. L., & Majeti, R. (2015). Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia. EXPERIMENTAL HEMATOLOGY, 43(12), 989–92.

Mutation in Wilms' Tumor 1 Induces DNA Hypermethylation of PRC2 Targets, Blocks Myelomonocytic Differentiation, and Defines a Novel Subtype of AML Responsive to EZH2 Inhibition
Thomas, D., Sinha, S., Yu, L., Jung, N., Dai, B., Gentles, A. J., … Majeti, R. (2014). Mutation in Wilms' Tumor 1 Induces DNA Hypermethylation of PRC2 Targets, Blocks Myelomonocytic Differentiation, and Defines a Novel Subtype of AML Responsive to EZH2 Inhibition. BLOOD, 124(21).

CRISPR/Cas9 and rAAV6-Mediated Targeted Integration at the CCR5 Locus in Hematopoietic Stem and Progenitor Cells
Bak, R. O., Dever, D. P., Saxena, N., Camarena, J., Reinisch, A., Wilkens, A. B., … Porteus, M. H. (2016). CRISPR/Cas9 and rAAV6-Mediated Targeted Integration at the CCR5 Locus in Hematopoietic Stem and Progenitor Cells. MOLECULAR THERAPY, 24, S19.

Deciphering the cancer methylome with Boolean implications to find novel drivers of aberrant DNA methylation and actionable drug targets
Sinha, S., Thomas, D., Majeti, R., & Dill, D. L. (2015). Deciphering the cancer methylome with Boolean implications to find novel drivers of aberrant DNA methylation and actionable drug targets. CANCER RESEARCH, 75(22).

Proffered Paper: Overcoming immune evasion in ovarian and breast cancer with anti-CD47 antibody blockade: A novel class of immune therapy
Volkmer, A. K., Willingham, S. B., Tseng, S. R., Ho, P. Y., Volkmer, J. P., Sikic, B. I., … Weissman, I. L. (2014). Proffered Paper: Overcoming immune evasion in ovarian and breast cancer with anti-CD47 antibody blockade: A novel class of immune therapy. EUROPEAN JOURNAL OF CANCER, 50, S13.

WILMS' TUMOR 1 MUTATION DRIVES DNA HYPERMETHYLATION IN AML AND RESPONDS TO EZH2-INHIBITOR
Thomas, D., Sinha, S., Gentles, A., Jung, N., Feinberg, A., Dill, D., & Majeti, R. (2014). WILMS' TUMOR 1 MUTATION DRIVES DNA HYPERMETHYLATION IN AML AND RESPONDS TO EZH2-INHIBITOR. EXPERIMENTAL HEMATOLOGY, 42(8), S62.

OVERCOMING IMMUNE EVASION IN PEDIATRIC BRAIN TUMORS: A PRE-CLINICAL DEVELOPMENT STUDY USING A HUMANIZED ANTI-CD47 ANTIBODY
Gholamin, S., Mitra, S., Feroze, A., Zhang, M., Esparza, R., Kahn, S., … Cheshier, S. (2014). OVERCOMING IMMUNE EVASION IN PEDIATRIC BRAIN TUMORS: A PRE-CLINICAL DEVELOPMENT STUDY USING A HUMANIZED ANTI-CD47 ANTIBODY. NEURO-ONCOLOGY, 16, 138.

The CD47 Macrophage Checkpoint as a New Immunotherapy Target
Sikic, B. I., Padda, S. K., Shah, S. A., Colevas, D., Narayanan, S., Fisher, G. A., … Weissman, I. L. (2017). The CD47 Macrophage Checkpoint as a New Immunotherapy Target. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia
Corces, M. R., Chang, H. Y., & Majeti, R. (2017). Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia. FRONTIERS IN ONCOLOGY, 7, 263.

SY-1425 (tamibarotene), a potent and selective RAR alpha agonist, induces changes in the transcriptional regulatory circuit of AML cells leading to differentiation
Fiore, C. M., McKeown, M. R., Lee, E., Eaton, M. L., Smith, D., Austgen, K., … Fritz, C. C. (2017). SY-1425 (tamibarotene), a potent and selective RAR alpha agonist, induces changes in the transcriptional regulatory circuit of AML cells leading to differentiation. CLINICAL CANCER RESEARCH, 23(24), 29–30.

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal
Valent, P., Akin, C., Arock, M., Bock, C., George, T. I., Galli, S. J., … Horny, H.-P. (2017). Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBIOMEDICINE, 26, 17–24.

Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models
Thomas, D., & Majeti, R. (2017). Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models. CANCER DISCOVERY, 7(5), 459–61.

Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells
Karamitros, D., Stoilova, B., Aboukhalil, Z., Hamey, F., Reinisch, A., Samitsch, M., … Vyas, P. (2018). Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells. NATURE IMMUNOLOGY, 19(1), 85-+.

Integrated Single-Cell Analysis Maps the Continuous Regulatory Landscape of Human Hematopoietic Differentiation
Buenrostro, J. D., Corces, M. R., Lareau, C. A., Wu, B., Schep, A. N., Aryee, M. J., … Greenleaf, W. J. (2018). Integrated Single-Cell Analysis Maps the Continuous Regulatory Landscape of Human Hematopoietic Differentiation. CELL, 173(6), 1535-+.

Identification of the Human Skeletal Stem Cell.
Chan, C. K., Gulati, G. S., Sinha, R., Tompkins, J. V., Lopez, M., Carter, A. C., … Longaker, M. T. (2018). Identification of the Human Skeletal Stem Cell. Cell, 175(1), 43.

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., … Smith, S. M. (2018). CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. The New England Journal of Medicine, 379(18), 1711–21.

Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation.
Minhas, P. S., Liu, L., Moon, P. K., Joshi, A. U., Dove, C., Mhatre, S., … Andreasson, K. I. (2018). Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation. Nature Immunology.

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.
Tvorogov, D., Thomas, D., Liau, N. P., Dottore, M., Barry, E. F., Lathi, M., … Lopez, A. F. (2018). Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Science Advances, 4(11), eaat3834.

Targeting Cancer Stemness in the Clinic: From Hype to Hope.
Saygin, C., Matei, D., Majeti, R., Reizes, O., & Lathia, J. D. (2018). Targeting Cancer Stemness in the Clinic: From Hype to Hope. Cell Stem Cell.

CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., … Mackall, C. L. (2019). CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

Induced pluripotent stem cell modeling of malignant hematopoiesis.
Chao, M. P., & Majeti, R. (2019). Induced pluripotent stem cell modeling of malignant hematopoiesis. Experimental Hematology.

Data mining for mutation-specific targets in acute myeloid leukemia.
Benard, B., Gentles, A. J., Kohnke, T., Majeti, R., & Thomas, D. (2019). Data mining for mutation-specific targets in acute myeloid leukemia. Leukemia.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., … Padda, S. K. (2019). First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1802018.

Accumulation of JAK Activation-Loop Phosphorylation Promotes Type I JAK Inhibitor Withdrawal Syndrome in Myelofibrosis
Tvorogov, D., Thomas, D., Liau, N. P. D., Dottore, M., Barry, E. F., Lathi, M., … Lopez, A. F. (2018). Accumulation of JAK Activation-Loop Phosphorylation Promotes Type I JAK Inhibitor Withdrawal Syndrome in Myelofibrosis. BLOOD, 132.

No Matter How You Splice It, RBM39 Inhibition Targets Spliceosome Mutant AML.
Thomas, R., & Majeti, R. (2019). No Matter How You Splice It, RBM39 Inhibition Targets Spliceosome Mutant AML. Cancer Cell, 35(3), 337–39.

Leukemic Stem Cell Gene Expression Signature and Clinical Outcomes in Acute Myeloid Leukemia Reply
Gentles, A. J., Majeti, R., & Alizadeh, A. A. (2011). Leukemic Stem Cell Gene Expression Signature and Clinical Outcomes in Acute Myeloid Leukemia Reply. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 305(11), 1094.

Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6
Bak, R. O., Dever, D. P., Reinisch, A., Hernandez, D. C., Majeti, R., & Porteus, M. H. (2017). Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6. ELIFE, 6.

Single-cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA.
Xu, J., Nuno, K., Litzenburger, U. M., Qi, Y., Corces, M. R., Majeti, R., & Chang, H. Y. (2019). Single-cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA. ELife, 8.

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.
Valent, P., Akin, C., Arock, M., Bock, C., George, T. I., Galli, S. J., … Horny, H.-P. P. (2017). Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBioMedicine, 26, 17–24.

Generation and use of a humanized bone-marrow-ossicle niche for hematopoietic xenotransplantation into mice.
Reinisch, A., Hernandez, D. C., Schallmoser, K., & Majeti, R. (2017). Generation and use of a humanized bone-marrow-ossicle niche for hematopoietic xenotransplantation into mice. Nature Protocols, 12(10), 2169–2188.

Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models.
Thomas, D., & Majeti, R. (2017). Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models. Cancer Discovery, 7(5), 459–461.

Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.
Majeti, R. (2014). Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia. Best Practice & Research. Clinical Haematology, 27(3-4), 229–34.

Barcoded Clonal Tracking of CRISPR-Cas9 and rAAV6-Mediated Gene Targeting in Human Hematopoietic Stem and Progenitor Cells
Dever, D. P., Sharma, R., Lee, C. M., Aziz, A., Koehnke, T., Camarena, J., … Porteus, M. (2019). Barcoded Clonal Tracking of CRISPR-Cas9 and rAAV6-Mediated Gene Targeting in Human Hematopoietic Stem and Progenitor Cells. MOLECULAR THERAPY, 27(4), 5.

Single-cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA
Xu, J., Nuno, K., Litzenburger, U. M., Qi, Y., Corces, M. R., Majeti, R., & Chang, H. Y. (2019). Single-cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA. ELIFE, 8.

Identification of the Human Skeletal Stem Cell
Chan, C. K. F., Gulati, G. S., Sinha, R., Tompkins, J. V., Lopez, M., Carter, A. C., … Longaker, M. T. (2018). Identification of the Human Skeletal Stem Cell. CELL, 175(1), 43-+.

Data mining for mutation-specific targets in acute myeloid leukemia
Benard, B., Gentles, A. J., Kohnke, T., Majeti, R., & Thomas, D. (2019). Data mining for mutation-specific targets in acute myeloid leukemia. LEUKEMIA, 33(4), 826–43.

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
Majzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., … Mackall, C. L. (2019). CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. CLINICAL CANCER RESEARCH, 25(8), 2560–74.

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., … Smith, S. M. (2018). CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 379(18), 1711–21.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Sikic, B., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., … Padda, S. K. (2019). First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. JOURNAL OF CLINICAL ONCOLOGY, 37(12), 946-+.

ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia
Zhu, L., Li, Q., Wong, S. H. K., Huang, M., Klein, B. J., Shen, J., … Cleary, M. L. (2016). ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia. CANCER DISCOVERY, 6(7), 770–83.

Single-cell mutational profiling of paired AML samples at diagnosis, remission and relapse: Implications for therapeutic resistance and MRD detection
Aleshin, A., Durruthy-Durruthy, R., Corces, R., Liedtke, M., Eastburn, D., & Majeti, R. (2019). Single-cell mutational profiling of paired AML samples at diagnosis, remission and relapse: Implications for therapeutic resistance and MRD detection. CANCER RESEARCH, 79(13).

Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index.
Li, Y., Thomas, D., Deutzmann, A., Majeti, R., Felsher, D. W., & Dill, D. L. (2019). Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. Scientific Reports, 9(1), 16775.

The Phosphatidylethanolamine Biosynthesis Pathway Provides a New Target for Cancer Chemotherapy.
Guan, Y., Chen, X., Wu, M., Zhu, W., Arslan, A., Takeda, S., … Peltz, G. (2019). The Phosphatidylethanolamine Biosynthesis Pathway Provides a New Target for Cancer Chemotherapy. Journal of Hepatology.

Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia.
Granja, J. M., Klemm, S., McGinnis, L. M., Kathiria, A. S., Mezger, A., Corces, M. R., … Greenleaf, W. J. (2019). Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia. Nature Biotechnology.

Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2.
Dutta, R., Zhang, T. Y., Köhnke, T., Thomas, D., Linde, M., Gars, E., … Majeti, R. (2020). Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2. The Journal of Clinical Investigation.

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies.
Chao, M. P., Takimoto, C. H., Feng, D. D., McKenna, K., Gip, P., Liu, J., … Majeti, R. (2019). Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies. Frontiers in Oncology, 9, 1380.

A Dysregulated DNA Methylation Landscape Linked to Gene Expression in MLL-Rearranged AML.
Koldobskiy, M. A., Abante, J., Jenkinson, G., Pujadas, E., Tetens, A., Zhao, F., … Feinberg, A. P. (2020). A Dysregulated DNA Methylation Landscape Linked to Gene Expression in MLL-Rearranged AML. Epigenetics, 1–18.

Single-cell mutational profiling enhances the clinical evaluation of AML MRD.
Ediriwickrema, A., Aleshin, A., Reiter, J. G., Corces, M. R., Köhnke, T., Stafford, M., … Majeti, R. (2020). Single-cell mutational profiling enhances the clinical evaluation of AML MRD. Blood Advances, 4(5), 943–52.

IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia.
Zhang, T. Y., Dutta, R., Benard, B., Zhao, F., Yin, R., & Majeti, R. (2020). IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia. Science Translational Medicine, 12(538).

Targeting macrophage checkpoint inhibitor SIRPa for anticancer therapy.
Liu, J., Xavy, S., Mihardja, S., Chen, S., Sompalli, K., Feng, D., … Volkmer, J.-P. P. (2020). Targeting macrophage checkpoint inhibitor SIRPa for anticancer therapy. JCI Insight.

A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.
Sikic, B. I., Lakhani, N. J., Patnaik, A., Shah, S., Chandana, S. R., Rasco, D. W., … Padda, S. K. (2018). A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
Azizi, A., Ediriwickrema, A., Dutta, R., Patel, S. A., Shomali, W., Medeiros, B., … Zhang, T. (2020). Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leukemia & Lymphoma, 1–8.

Sufficiency for inducible Caspase-9 safety switch in human pluripotent stem cells and disease cells.
Nishimura, T., Xu, H., Iwasaki, M., Karigane, D., Saavedra, B., Takahashi, Y., … Nakauchi, H. (2020). Sufficiency for inducible Caspase-9 safety switch in human pluripotent stem cells and disease cells. Gene Therapy.

Multiomic single cell analysis of normal human bone marrow identifies a unique stem and progenitor population that expands in AML
Ediriwickrema, A., Ramakrishnan, S., Nakamoto, M., Ghanekar, S., Luca, B., Newman, A., … Majeti, R. (2020). Multiomic single cell analysis of normal human bone marrow identifies a unique stem and progenitor population that expands in AML. Cancer Res, 80(16).

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.
Zhang, H., Nakauchi, Y., Köhnke, T., Stafford, M., Bottomly, D., Thomas, R., … Tyner, J. W. (2020). Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nature Cancer, 1(8), 826–39.

CD34 expression does not correlate with immunophenotypic stem cell or progenitor content in human cord blood products.
Mantri, S., Reinisch, A., Dejene, B. T., Lyell, D. J., DiGiusto, D. L., Agarwal-Hashmi, R., … Porteus, M. H. (2020). CD34 expression does not correlate with immunophenotypic stem cell or progenitor content in human cord blood products. Blood Advances, 4(21), 5357–61.

Targeting LSCs: Peeling Back the Curtain on the Metabolic Complexities of AML.
Zhang, T. Y., & Majeti, R. (2020). Targeting LSCs: Peeling Back the Curtain on the Metabolic Complexities of AML. Cell Stem Cell, 27(5), 693–95.

Reprogramming leukemia cells into antigen presenting cells as a novel cancer vaccination immunotherapy
Linde, M. H., Dove, C. G., Gurev, S. F., Phan, P., Zhao, F., Gars, E. J., … Majeti, R. (2020). Reprogramming leukemia cells into antigen presenting cells as a novel cancer vaccination immunotherapy. JOURNAL OF IMMUNOLOGY. AMER ASSOC IMMUNOLOGISTS.

The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells.
Sharma, R., Dever, D. P., Lee, C. M., Azizi, A., Pan, Y., Camarena, J., … Majeti, R. (2021). The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells. Nature Communications, 12(1), 472.

Gene replacement of alpha-globin with beta-globin restores hemoglobin balance in beta-thalassemia-derived hematopoietic stem and progenitor cells.
Cromer, M. K., Camarena, J., Martin, R. M., Lesch, B. J., Vakulskas, C. A., Bode, N. M., … Porteus, M. H. (2021). Gene replacement of alpha-globin with beta-globin restores hemoglobin balance in beta-thalassemia-derived hematopoietic stem and progenitor cells. Nature Medicine.

Targeting Cancer Stemness in the Clinic: From Hype to Hope
Saygin, C., Matei, D., Majeti, R., Reizes, O., & Lathia, J. D. (2019). Targeting Cancer Stemness in the Clinic: From Hype to Hope. CELL STEM CELL, 24(1), 25–40.

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
Tvorogov, D., Thomas, D., Liau, N. P. D., Dottore, M., Barry, E. F., Lathi, M., … Lopez, A. F. (2018). Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. SCIENCE ADVANCES, 4(11).

Generation and use of a humanized bone-marrow-ossicle niche for hematopoietic xenotransplantation into mice
Reinisch, A., Hernandez, D. C., Schallmoser, K., & Majeti, R. (2017). Generation and use of a humanized bone-marrow-ossicle niche for hematopoietic xenotransplantation into mice. NATURE PROTOCOLS, 12(10), 2169–2188.

Biology and relevance of human acute myeloid leukemia stem cells
Thomas, D., & Majeti, R. (2017). Biology and relevance of human acute myeloid leukemia stem cells. BLOOD, 129(12), 1577–1585.

Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.
Romine, K. A., Nechiporuk, T., Bottomly, D., Jeng, S., McWeeney, S. K., Kaempf, A., … Tyner, J. W. (2021). Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia. Cancer Discovery.

Clonal hematopoiesis: from mechanisms to clinical intervention.
Kohnke, T., & Majeti, R. (2021). Clonal hematopoiesis: from mechanisms to clinical intervention. Cancer Discovery.

Reprogramming cancer into antigen presenting cells as a novel immunotherapy.
Linde, M. H., Gurev, S. F., Phan, P., Zhao, F., Gars, E. J., Stafford, M., … Majeti, R. (2021). Reprogramming cancer into antigen presenting cells as a novel immunotherapy. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.
Romine, K. A., Nechiporuk, T., Bottomly, D., Jeng, S., McWeeney, S. K., Kaempf, A., … Tyner, J. W. (2021). Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia. Blood Cancer Discovery, 2(5), 518–531.

NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity.
Richards, R. M., Zhao, F., Freitas, K. A., Parker, K. R., Xu, P., Fan, A., … Mackall, C. L. (2021). NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity. Blood Cancer Discovery, 2(6), 648–665.

Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia.
Benard, B. A., Leak, L. B., Azizi, A., Thomas, D., Gentles, A. J., & Majeti, R. (1800). Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia. Nature Communications, 12(1), 7244.

Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
Theruvath, J., Menard, M., Smith, B. A., Linde, M. H., Coles, G. L., Dalton, G. N., … Majzner, R. G. (1800). Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nature Medicine.

CytofIn enables integrated analysis of public mass cytometry datasets using generalized anchors.
Lo, Y.-C., Keyes, T. J., Jager, A., Sarno, J., Domizi, P., Majeti, R., … Davis, K. L. (2022). CytofIn enables integrated analysis of public mass cytometry datasets using generalized anchors. Nature Communications, 13(1), 934.

The cell type specific 5hmC landscape and dynamics of healthy human hematopoiesis and TET2-mutant pre-leukemia.
Nakauchi, Y., Azizi, A., Thomas, D., Corces, M. R., Reinisch, A., Sharma, R., … Majeti, R. (2022). The cell type specific 5hmC landscape and dynamics of healthy human hematopoiesis and TET2-mutant pre-leukemia. Blood Cancer Discovery.

Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia.
Bassal, M. A., Samaraweera, S. E., Lim, K., Bernard, B. A., Bailey, S., Kaur, S., … D'Andrea, R. J. (2022). Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nature Communications, 13(1), 2614.

Reengineering Ponatinib to Minimize Cardiovascular Toxicity.
Hnatiuk, A. P., Bruyneel, A. A., Tailor, D., Pandrala, M., Dheeraj, A., Li, W., … Mercola, M. (2022). Reengineering Ponatinib to Minimize Cardiovascular Toxicity. Cancer Research.

Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.
Mabe, N. W., Huang, M., Dalton, G. N., Alexe, G., Schaefer, D. A., Geraghty, A. C., … Majzner, R. G. (2022). Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1. Nature Cancer.

Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia.
Bassal, M. A., Samaraweera, S. E., Lim, K., Benard, B. A., Bailey, S., Kaur, S., … D'Andrea, R. J. (2022). Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nature Communications, 13(1), 4131.

Single cell genomics in AML: extending the frontiers of AML research.
Ediriwickrema, A., Gentles, A. J., & Majeti, R. (2022). Single cell genomics in AML: extending the frontiers of AML research. Blood.

Reengineering Ponatinib to Minimize Cardiovascular Toxicity
Hnatiuk, A. P., Bruyneel, A. A. N., Tailor, D., Pandrala, M., Dheeraj, A., Li, W., … Mercola, M. (2022). Reengineering Ponatinib to Minimize Cardiovascular Toxicity. CANCER RESEARCH, 82(15), 2777–2791.

MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS).
Chen, J., Johnson, L., McKenna, K., Choi, T., Duan, J., Feng, D., … Weissman, I. (2022). MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS). Clinical Lymphoma, Myeloma & Leukemia, 22 Suppl 2, S317–S318.

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.
Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., … Kantarjian, H. M. (2022). TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discovery, OF1–OF14.

An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS).
Stahl, M., Abdel-Wahab, O., Wei, A. H., Savona, M. R., Xu, M. L., Xie, Z., … Zeidan, A. M. (2022). An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS). Blood Advances.

Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
Zeidan, A. M., Bewersdorf, J. P., Buckstein, R., Sekeres, M. A., Steensma, D. P., Platzbecker, U., … Santini, V. (2022). Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia.

Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS).
Chen, J. Y., Johnson, L., McKenna, K. M., Choi, T. S., Duan, J., Feng, D., … Weissman, I. L. (2022). Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability.
Thomas, D., Wu, M., Nakauchi, Y., Zheng, M., Thompson-Peach, C. A., Lim, K., … Majeti, R. (2022). Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability. Cancer Discovery.

IL-3 SELECTIVELY RESCUES RUNX1-DEFICIENT HUMAN HSPCS WITH DYSREGULATED JAK/ STAT SIGNALING
Fan, A., Azizi, A., Nuno, K., Nakauchi, Y., Zhao, F., Cruz-Hernandez, D., … Majeti, R. (2022). IL-3 SELECTIVELY RESCUES RUNX1-DEFICIENT HUMAN HSPCS WITH DYSREGULATED JAK/ STAT SIGNALING. EXPERIMENTAL HEMATOLOGY. ELSEVIER SCIENCE INC.

Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy.
Linde, M. H., Fan, A. C., Kohnke, T., Trotman-Grant, A. C., Gurev, S. F., Phan, P., … Majeti, R. (2023). Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy. Cancer Discovery.

Lineage plasticity dictates responsiveness to anti-GD2 therapy in neuroblastoma.
Mabe, N. W., Huang, M., Schaefer, D. A., Dalton, G. N., Digiovanni, G., Alexe, G., … Majzner, R. G. (2022). Lineage plasticity dictates responsiveness to anti-GD2 therapy in neuroblastoma. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Targeting IDH1-Mutated Pre-Leukemic Hematopoietic Stem Cells in Myeloid Disease, Including CCUS and AML
Landberg, N., Koehnke, T., Nakauchi, Y., Fan, A., Karigane, D., Thomas, D., & Majeti, R. (2022). Targeting IDH1-Mutated Pre-Leukemic Hematopoietic Stem Cells in Myeloid Disease, Including CCUS and AML. BLOOD. AMER SOC HEMATOLOGY.

Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
Chen, J., Johnson, L., McKenna, K., Choi, T., Duan, J., Feng, D., … Weissman, I. (2022). Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.

Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia.
Kotini, A. G., Carcamo, S., Cruz-Rodriguez, N., Olszewska, M., Wang, T., Demircioglu, D., … Papapetrou, E. P. (2023). Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia. Blood Cancer Discovery, OF1–OF18.

RUNX1 loss renders hematopoietic and leukemic cells dependent on interleukin-3 and sensitive to JAK inhibition.
Fan, A. C., Nakauchi, Y., Bai, L., Azizi, A., Nuno, K. A., Zhao, F., … Majeti, R. (2023). RUNX1 loss renders hematopoietic and leukemic cells dependent on interleukin-3 and sensitive to JAK inhibition. The Journal of Clinical Investigation.

Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells.
Nelde, A., Schuster, H., Heitmann, J. S., Bauer, J., Maringer, Y., Zwick, M., … Walz, J. S. (2023). Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. Blood Cancer Discovery, OF1–OF22.

Convergent Epigenetic Evolution Drives Relapse in Acute Myeloid Leukemia.
Nuno, K. A., Azizi, A., Kohnke, T., Lareau, C. A., Ediwirickrema, A., Ryan Corces, M., … Majeti, R. (2023). Convergent Epigenetic Evolution Drives Relapse in Acute Myeloid Leukemia. BioRxiv : the Preprint Server for Biology.